Effect and Safety Study of Atorvastatin to Treat Chronic Subdural Hematoma

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

September 30, 2016

Conditions
Chronic Subdural Hematoma
Interventions
DRUG

Atorvastatin

20 mg (every evening orally) for 8 weeks

DRUG

placebo

20 mg (every evening orally) for 8 weeks

Trial Locations (31)

300052

Tianjin Medical University General Hospital, Tianjin

Unknown

Beijing tiantan hospital, Beijing

Chinese PLA General Hospital, Beijing

Peking union medical college hospital, Beijing

Cangzhou centerl hospital, Cangzhou

Xiangya hospital central southe university, Changsha

Southwest hospital, Chongqing

West china hospital, Chongqing

The first affiliated hospital of Fujian medical university, Fuzhou

Nanfang hospital, Guangzhou

First Affiliated Hospital of Harbin Medical University, Haerbing

Hainan general hospital, Haikou

117 Hospital of People's Liberation Army, Hangzhou

The second Affiliated hospital of zhejiang university school of medicine, Hangzhou

Anhui provincial hospital, Hefei

Inner mongolia people's hospital, Hohehot

Qilu hospital of shandong university, Jinan

Linyi People's Hospital, Linyi

Jiangsu province hospital, Nanjing

Ordos Central Hospital, Ordos

Changzheng Hospital, Shanghai

Huashan hospital, Shanghai

The second hospital of Hebei medical university, Shijiazhuang

The first hospital of Shanxi medical university, Taiyuan

Tongji hospital, Wuhan

Tangdu hospital, Xi'an

Xijing Hospital, Xi'an

Prince of Wales Hospital, Xianggang

The Affiliated Hospital of Xuzhou Medical College, Xuzhou

General Hospital of Ningxia Medical University, Yinchuan

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Oriental Neurosurgery Evidence-Based-Study Team

OTHER

NCT02024373 - Effect and Safety Study of Atorvastatin to Treat Chronic Subdural Hematoma | Biotech Hunter | Biotech Hunter